Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
← catalyst calendarNCT06422689 · readout in 168 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Premier HealthCare Solutions Inc..
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,511actual
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-10 | actual | When the study began enrolling |
| Primary completion | 2027-02-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-03 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Intervention
- Drug: Albuterol and budesonide inhalation aerosol — also filed as PT027
Primary outcome
what the primary-completion date above is the date OFAsthma exacerbation
measured During 12-month pre-switch and 12-month post-switch periods
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed